Screening of Potential Key Biomarkers for Ewing Sarcoma: Evidence from Gene Array Analysis.
Ewing sarcoma
biomarkers
differentially expressed genes
microarray
protein interaction
Journal
International journal of general medicine
ISSN: 1178-7074
Titre abrégé: Int J Gen Med
Pays: New Zealand
ID NLM: 101515487
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
11
2021
accepted:
02
02
2022
entrez:
28
3
2022
pubmed:
29
3
2022
medline:
29
3
2022
Statut:
epublish
Résumé
Ewing's sarcoma (ES) is a common bone cancer in children and adolescents. There are ethnic differences in the incidence and treatment effects. People have made great efforts to clarify the cause; however, the molecular mechanism of ES is still poorly understood. We download the microarray datasets GSE68776, GSE45544 and GSE17674 from the Gene Expression Omnibus (GEO) database. The differentially expressed genes (DEGs) of the three datasets were screened and enrichment analysis was performed. STRING and Cytoscape were used to carry out module analysis, building a protein-protein interaction (PPI) network. Finally, a series of analyses such as survival analysis and immune infiltration analysis were performed on the selected genes. A total of 629 differentially expressed genes were screened, including 206 up-regulated genes and 423 down-regulated genes. The pathways and rich-functions of DEGs include protein activation cascade, carbohydrate binding, cell-cell adhesion junctions, mitotic cell cycle, p53 pathway, and cancer pathways. Then, a total of 10 hub genes were screened out. Biological process analysis showed that these genes were mainly enriched in mitotic nuclear division, protein kinase activity, cell division, cell cycle, and protein phosphorylation. Survival analysis and multiple gene comparison analysis showed that CDCA8, MAD2L1 and FANCI may be involved in the occurrence and prognosis of ES. The purpose of our study is to clarify the DEG and key genes, which will help us know more about the molecular mechanisms of ES, provide potential pathway or targets for the diagnosis and treatment.
Sections du résumé
Background
UNASSIGNED
Ewing's sarcoma (ES) is a common bone cancer in children and adolescents. There are ethnic differences in the incidence and treatment effects. People have made great efforts to clarify the cause; however, the molecular mechanism of ES is still poorly understood.
Methods
UNASSIGNED
We download the microarray datasets GSE68776, GSE45544 and GSE17674 from the Gene Expression Omnibus (GEO) database. The differentially expressed genes (DEGs) of the three datasets were screened and enrichment analysis was performed. STRING and Cytoscape were used to carry out module analysis, building a protein-protein interaction (PPI) network. Finally, a series of analyses such as survival analysis and immune infiltration analysis were performed on the selected genes.
Results
UNASSIGNED
A total of 629 differentially expressed genes were screened, including 206 up-regulated genes and 423 down-regulated genes. The pathways and rich-functions of DEGs include protein activation cascade, carbohydrate binding, cell-cell adhesion junctions, mitotic cell cycle, p53 pathway, and cancer pathways. Then, a total of 10 hub genes were screened out. Biological process analysis showed that these genes were mainly enriched in mitotic nuclear division, protein kinase activity, cell division, cell cycle, and protein phosphorylation.
Conclusion
UNASSIGNED
Survival analysis and multiple gene comparison analysis showed that CDCA8, MAD2L1 and FANCI may be involved in the occurrence and prognosis of ES. The purpose of our study is to clarify the DEG and key genes, which will help us know more about the molecular mechanisms of ES, provide potential pathway or targets for the diagnosis and treatment.
Identifiants
pubmed: 35342299
doi: 10.2147/IJGM.S346251
pii: 346251
pmc: PMC8943648
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2575-2588Informations de copyright
© 2022 Zhong et al.
Déclaration de conflit d'intérêts
The authors of this article declare that they have no conflicts of interest related to this work.
Références
Epigenetics. 2014 Dec;9(12):1613-25
pubmed: 25625846
Biochem Biophys Res Commun. 2013 Jul 12;436(4):711-8
pubmed: 23791740
Clin Cancer Res. 2006 Jan 1;12(1):83-8
pubmed: 16397028
Sci Rep. 2017 Sep 6;7(1):10660
pubmed: 28878254
Tumour Biol. 2014 May;35(5):4257-65
pubmed: 24375198
BMC Bioinformatics. 2003 Jan 13;4:2
pubmed: 12525261
Clin Cancer Res. 2015 Nov 1;21(21):4935-46
pubmed: 26179511
Am J Surg Pathol. 1983 Jun;7(4):309-18
pubmed: 6869663
Bioinformatics. 2011 Feb 1;27(3):431-2
pubmed: 21149340
Novartis Found Symp. 2002;247:91-101; discussion 101-3, 119-28, 244-52
pubmed: 12539951
Pharmgenomics Pers Med. 2019 Jan 17;12:9-14
pubmed: 30697061
Exp Oncol. 2020 Dec;42(4):333-336
pubmed: 33355873
BMC Syst Biol. 2014;8 Suppl 4:S11
pubmed: 25521941
CA Cancer J Clin. 2014 Mar-Apr;64(2):83-103
pubmed: 24488779
Science. 2011 Jul 15;333(6040):312-6
pubmed: 21764741
Cancer Res. 2017 Nov 1;77(21):e108-e110
pubmed: 29092952
Protein J. 2017 Feb;36(1):1-6
pubmed: 28108801
Front Oncol. 2021 Mar 12;11:587554
pubmed: 33777739
Life Sci. 2021 Aug 1;278:119499
pubmed: 33865878
PLoS One. 2015 Aug 19;10(8):e0136246
pubmed: 26287798
Cancer Cell Int. 2019 Oct 11;19:264
pubmed: 31632198
Mol Med Rep. 2020 Oct;22(4):2916-2924
pubmed: 32945371
N Engl J Med. 1994 Aug 4;331(5):294-9
pubmed: 8022439
Urol Oncol. 2016 May;34(5):237.e1-10
pubmed: 26706119
Cancer. 2009 Apr 1;115(7):1531-43
pubmed: 19197972
Nucleic Acids Res. 2013 Jan;41(Database issue):D808-15
pubmed: 23203871
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
Exp Cell Res. 2006 Apr 15;312(7):962-73
pubmed: 16427043
Nat Biotechnol. 2020 Jun;38(6):675-678
pubmed: 32444850
Proc Natl Acad Sci U S A. 2019 Feb 12;116(7):2561-2570
pubmed: 30692263
Cancers (Basel). 2021 Mar 02;13(5):
pubmed: 33801424
Cancer Res. 2007 May 1;67(9):4113-22
pubmed: 17483322
Nucleic Acids Res. 2007;35(5):1638-48
pubmed: 17308347
Virchows Arch A Pathol Anat Histopathol. 1984;404(3):313-24
pubmed: 6149650
Cancer Discov. 2019 Feb;9(2):230-247
pubmed: 30373918
J Pediatr Hematol Oncol. 2008 Jun;30(6):425-30
pubmed: 18525458
ISRN Oncol. 2011;2011:168712
pubmed: 22084725
Diabetes. 2007 Sep;56(9):2349-55
pubmed: 17563058
Rev Bras Ortop. 2015 Dec 08;47(4):446-50
pubmed: 27047848
J Korean Med Sci. 2001 Aug;16(4):424-32
pubmed: 11511787
J Natl Compr Canc Netw. 2017 Feb;15(2):155-167
pubmed: 28188186
Onco Targets Ther. 2020 Jan 15;13:451-463
pubmed: 32021289
Bioinformatics. 2005 Aug 15;21(16):3448-9
pubmed: 15972284
Clin Cancer Res. 2021 Jul 15;27(14):4012-4024
pubmed: 33879459
Neurogenetics. 2006 May;7(2):67-80
pubmed: 16572319
PLoS Genet. 2014 Jul 10;10(7):e1004475
pubmed: 25010205
Nucleic Acids Res. 2007 Jan;35(Database issue):D760-5
pubmed: 17099226
Int J Biol Sci. 2021 Mar 15;17(5):1178-1190
pubmed: 33867838
Genes Chromosomes Cancer. 2014 Jul;53(7):622-33
pubmed: 24723486
Cancer Sci. 2019 Jul;110(7):2133-2144
pubmed: 31066149
Genome Biol. 2016 Aug 22;17(1):174
pubmed: 27549193
Biomed Pharmacother. 2017 Aug;92:1038-1044
pubmed: 28609841
Chromosoma. 2006 Aug;115(4):288-95
pubmed: 16565862
Liver Int. 2012 Mar;32(3):420-8
pubmed: 22192146
Mol Biol Rep. 2020 Oct;47(10):7831-7842
pubmed: 33009967
Genome Biol. 2007;8(9):R183
pubmed: 17784955
Cell Death Dis. 2017 Mar 16;8(3):e2680
pubmed: 28300828
Med Oncol. 2014 Nov;31(11):248
pubmed: 25260804
Neoplasia. 2004 Jan-Feb;6(1):1-6
pubmed: 15068665
Pathol Res Pract. 2018 Feb;214(2):213-216
pubmed: 29254787
Onco Targets Ther. 2019 Dec 19;12:11313-11324
pubmed: 31908496
Science. 1996 Oct 11;274(5285):246-8
pubmed: 8824189
J Virol. 2010 Oct;84(19):9718-32
pubmed: 20660191
Am J Surg Pathol. 1984 Dec;8(12):885-98
pubmed: 6083729
Cancer Discov. 2014 Nov;4(11):1326-41
pubmed: 25186949
Cancer Discov. 2014 Nov;4(11):1342-53
pubmed: 25223734
Nucleic Acids Res. 2020 Jul 2;48(W1):W509-W514
pubmed: 32442275
PLoS Genet. 2013 Mar;9(3):e1003368
pubmed: 23555285